-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The complex of the bispecific antibody AFM13 with NK cells continued to induce remission in patients with relapsed CD30 + lymphoma
+ lymphoma
AFM13 is able to target CD16A and CD30, pre-complexed with cord blood-derived allogeneic NK cells in CD30 + relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma patients with median prior treatment Line is 7
+ The median prior line of therapy for these patients was 7 The median prior line of therapy for these patients was 7
After undergoing immune cell dissection, subjects received two cycles of AFM13-NK cell complexes, up to 100 million cells/kg, administered to 13 patients and selected for Phase II evaluation
immunity
Of the 19 evaluable patients, 17 responded to treatment, resulting in an overall response rate (ORR) of 89%
Of the 19 evaluable patients, 17 responded to treatment, resulting in an overall response rate (ORR) of 89%
Original source:
Original source:https://firstwordpharma.
https://firstwordpharma.
com/story/5545475 https://firstwordpharma.
com/story/5545475
Leave a comment here